Literature DB >> 9498963

CD4 lymphocyte counts and mortality in AIDS patients requiring mechanical ventilator support due to Pneumocystis carinii pneumonia.

S D Kumar1, B P Krieger.   

Abstract

OBJECTIVE: To evaluate CD4 counts as a predictor of mortality in AIDS patients with respiratory failure due to Pneumocystis carinii pneumonia (PCP).
DESIGN: Retrospective chart review.
SETTING: Urban university medical center. PATIENTS: Forty-eight patients admitted to the medical ICU from January 1993 to August 1996 with diagnosis of HIV/AIDS, PCP, CD4 count <200 cells per cubic millimeter, who required mechanical ventilation for respiratory failure.
INTERVENTIONS: Medical records were reviewed and age, CD4 count, lactate dehydrogenase, room air (RA) PaO2, coinfections, and day of admission to day of intubation (DOA-DOI) data were recorded.
RESULTS: All 48 patients (12 women and 36 men) were treated with corticosteroids and IV trimethoprim-sulfamethoxazole. Age ranged from 21 to 65 years; CD4, 1 to 180, RA PaO2, 27 to 93 mm Hg; and DOA-DOI, 0 to 20 days. Mortality varied significantly depending on CD4 counts: CD4 0 to 10 (100%); CD4 11 to 50 (88%); CD4 51 to 100 (50%); and CD4 >100 (25%). There were no significant difference in mortality between the groups with DOA-DOI <5 days (82%) vs >5 days (80%) or between the groups with PaO2 <60 mm Hg (85%) vs PaO2 >60 mm Hg (73%).
CONCLUSION: Even though overall mortality was 81%, the mortality rate was significantly different among the four groups. Most striking was the progressive increase in mortality as CD4 cells decreased from >100 (25% mortality) to <10 (100% mortality). Survivors had significantly higher CD4 cell counts than those who died. The CD4 cell count within 2 weeks of admission has significant prognostic value and may be helpful when counseling patients, families, and healthcare surrogates in end-of-life decision making.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498963     DOI: 10.1378/chest.113.2.430

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 2.  The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia.

Authors:  R J Boyton; D M Mitchell; O M Kon
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

3.  Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy.

Authors:  R F Miller; E Allen; A Copas; M Singer; S G Edwards
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

4.  Short- and long-term outcome of HIV-infected patients admitted to the intensive care unit.

Authors:  S F L van Lelyveld; C M Wind; T Mudrikova; H J van Leeuwen; D W de Lange; A I M Hoepelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-18       Impact factor: 3.267

5.  Intensive Care Usage by HIV-Positive Patients in the HAART Era.

Authors:  L Turtle; R Vyakernam; A Menon-Johansson; M R Nelson; N Soni
Journal:  Interdiscip Perspect Infect Dis       Date:  2011-10-30

6.  Lymphocyte subset analysis to evaluate the prognosis of HIV-negative patients with pneumocystis pneumonia.

Authors:  Fan Jin; Jing Xie; Huan-Ling Wang
Journal:  BMC Infect Dis       Date:  2021-05-14       Impact factor: 3.090

7.  Pneumocystis jirovecii Pneumonia in Patients with Nephrotic Syndrome: Application of Lymphocyte Subset Analysis in Predicting Clinical Outcomes.

Authors:  Yang Liu; Ke Zheng; Yecheng Liu; Huadong Zhu
Journal:  Can J Infect Dis Med Microbiol       Date:  2020-02-20       Impact factor: 2.471

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.